Filing Details
TScan Therapeutics, Inc. (NASDAQ:TCRX) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
8k filedNASDAQ:TCRX
TScan Therapeutics, Inc. (TCRX) Reports Material Event to SEC
TScan Therapeutics, Inc. (NASDAQ:TCRX) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
At publication ·
What changed
TScan Therapeutics, Inc. (NASDAQ:TCRX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- TScan Therapeutics, Inc. (NASDAQ: TCRX) filed a Form 8-K with the SEC on August 12, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $0.77 with a market capitalization of $61.0 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
TScan Therapeutics, Inc.'s stock currently trades at $0.77 with a market capitalization of $61.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for TScan Therapeutics, Inc.'s stock.
All SEC filings for TScan Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TCRX Stock Page
Frequently Asked Questions
Where can I read TCRX's SEC filings?
Browse all filings on our TCRX SEC filings page.
What types of SEC filings does TScan Therapeutics, Inc. file?
Public companies like TScan Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.